Skip to content
Yog Pharma
CardiovascularCholesterol absorption inhibitor

Ezetimibe is a cholesterol absorption inhibitor indicated for primary hyperlipidemia, alone or with a statin. We supply it to US manufacturers of tablets and fixed-dose combinations.

CAS163222-33-1409.4 g/molC24H21F2NO3
2D structure of Ezetimibe.

Data from PubChem (CID 150311) and FDA’s substance registry

CAS number

163222-33-1

Molecular formula

C24H21F2NO3

Molecular weight

409.4g/mol

FDA UNII

IUPAC name

(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one

InChIKey

OLNTVTPDXPETLC-XPWALMASSA-N

Appearance
White to off-white crystalline powder.
Solubility
Practically insoluble in water. Freely soluble in methanol and acetone, and soluble in ethanol.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

Practically insoluble in water, so most formulations need micronized material. State the particle size you developed with.

On the US market

Reference product
ZetiaNDA 021445
Approved ANDAs
11 with a marketed product
Approved forms and strengths
  • Tablet 10 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com